<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Hepatic ductopenia and vanishing bile duct syndrome in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Hepatic ductopenia and vanishing bile duct syndrome in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Hepatic ductopenia and vanishing bile duct syndrome in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nancy Reau, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sanjiv Chopra, MD, MACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristen M Robson, MD, MBA, FACG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 22, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vanishing bile duct syndrome (VBDS) is an uncommon, acquired, but potentially serious form of chronic cholestatic liver disease. Hepatic ductopenia (a pathologic description; also designated as bile duct paucity) refers to a reduction in the number of intrahepatic bile ducts, a process that may ultimately lead to cholestatic liver disease and can progress to biliary cirrhosis. VBDS is manifested histologically by severe bile duct destruction, defined as a loss of the intralobular bile ducts in &gt;50 percent of portal areas. This topic will discuss the etiology, clinical features, diagnosis, and management of acquired hepatic ductopenia and VBDS.
        </p>
        <p>
         Genetic and congenital diseases that are associated with disorders of the bile ducts are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Syndromic (ie, Alagille syndrome) and nonsyndromic varieties of paucity of interlobular bile ducts (see
         <a class="medical medical_review" href="/z/d/html/3584.html" rel="external">
          "Inherited disorders associated with conjugated hyperbilirubinemia"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cystic fibrosis (see
         <a class="medical medical_review" href="/z/d/html/6367.html" rel="external">
          "Cystic fibrosis: Clinical manifestations and diagnosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alpha-1 antitrypsin deficiency (see
         <a class="medical medical_review" href="/z/d/html/1429.html" rel="external">
          "Extrapulmonary manifestations of alpha-1 antitrypsin deficiency"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Trihydroxycoprostanic acidemia; trisomies 17, 18, 21 (see
         <a class="medical medical_review" href="/z/d/html/452.html" rel="external">
          "Congenital cytogenetic abnormalities"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extrahepatic bile duct atresia and paucity of interlobular bile ducts (see
         <a class="medical medical_review" href="/z/d/html/5945.html" rel="external">
          "Causes of cholestasis in neonates and young infants"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Causes of cholestasis in neonates and young infants are discussed separately (see
         <a class="medical medical_review" href="/z/d/html/5945.html" rel="external">
          "Causes of cholestasis in neonates and young infants"
         </a>
         )
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          NORMAL BILIARY TREE ANATOMY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The biliary tree is the tubular system of ducts that transports bile from the liver to the small intestine. It is divided into intra- and extrahepatic systems. Few disease states involve both systems, thus allowing for a natural taxonomic separation between the intra- and extrahepatic biliary tree [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The extrahepatic system includes the right and left hepatic ducts, cystic duct, and common bile duct.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The intrahepatic biliary tree contains ducts proximal to the right and left hepatic ducts [
         <a href="#rid2">
          2
         </a>
         ]. The intrahepatic system is further divided into intrahepatic large bile ducts (segmental and area ducts) that are grossly visible, and the intrahepatic small bile ducts (interlobular bile ducts and periportal bile ductules [canals of Hering]).
        </p>
        <p>
        </p>
        <p>
         The diameter of the bile ducts steadily decreases from the liver hilum toward the periphery. The bile ducts, as well as branches of the hepatic artery and portal vein, form a triad in the portal tract. Interlobular bile ducts are identified in portal tracts near arterial branches of similar size.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of VBDS is not well understood; however, immunologic injury has been implicated in bile duct loss, and T-cell mediated immunologic reaction may lead to epithelial cell apoptosis [
         <a href="#rid3">
          3
         </a>
         ]. Biliary apoptosis is implicated in the pathogenesis of multiple cholangiopathies and may actually be underappreciated due to the difficulty in accurately identifying apoptotic biliary cells in hematoxylin and eosin-stained specimens.
        </p>
        <p>
         Biliary homeostasis exists as a balance between apoptosis and regeneration. Liver stem cells from the canals of Hering are likely the source of new biliary cells, a process regulated via B cell lymphoma (BCL)-2 proteins [
         <a href="#rid2">
          2,4
         </a>
         ]. BAX (BCL-2 associated X protein), an apoptosis promoter, and BCL-2, which regulates apoptosis, are both expressed on bile duct cells. However, BAX is expressed along the entire biliary tree, whereas BCL-2 appears to be limited to bile ductules and interlobular bile ducts.
        </p>
        <p class="headingAnchor" id="H4191237497">
         <span class="h1">
          CAUSES OF DUCTOPENIA
         </span>
        </p>
        <p class="headingAnchor" id="H1117561755">
         <span class="h2">
          Drug-induced liver injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         Drug-induced liver injury can lead to cholestasis (defined as elevated alkaline phosphatase ≥2 times the upper limit of normal)  (
         <a class="graphic graphic_table graphicRef76892" href="/z/d/graphic/76892.html" rel="external">
          table 1
         </a>
         ), and some patients with DILI may progress to VBDS despite discontinuing the offending agent. Drugs that have been implicated in causing VBDS include:
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         /clavulanate, other penicillins, macrolide antibiotics, fluoroquinolones, sulfonamides, antifungal agents, nonsteroidal anti-inflammatory agents, phenothiazines, tricyclic antidepressants, and anticonvulsants [
         <a href="#rid5">
          5-9
         </a>
         ]. The National Institutes of Health maintains a
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548715%2F%23Phenotypes_vbds.Drugs_Associated_with_Va&amp;token=%2FoasTEv5%2B3spYf8zZxJJot7UarezM9i00QW22svleZdL1zVmusb9qGBkkToRvOo0YMtiyLXSTiiUrs%2FqlkiWD%2BAIsInm2lpg8z%2Bf1yn8fsrUemZ2EeVdub%2F%2BWOUdXXZD&amp;TOPIC_ID=3595" target="_blank">
          database
         </a>
         of drugs and herbal medicines that have been associated with VBDS. (See
         <a class="medical medical_review" href="/z/d/html/3568.html" rel="external">
          "Drugs and the liver: Metabolism and mechanisms of injury"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3571.html" rel="external">
          "Drug-induced liver injury"
         </a>
         .)
        </p>
        <p>
         Patients with DILI typically present with jaundice and pruritus one to six months after the onset of bile duct injury [
         <a href="#rid9">
          9
         </a>
         ]. Symptoms and liver biochemical and function tests may ultimately improve; however, progressive bile duct loss can lead to cirrhosis, liver failure, and death or liver transplantation [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2784370039">
         <span class="h2">
          Immune-mediated disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immune-mediated disorders that have been associated with bile duct inflammation and loss include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary biliary cholangitis – Primary biliary cholangitis (PBC) is a known cause of destruction of the interlobular bile ducts; however, this pathognomonic biopsy finding for PBC is seen infrequently. Periductular granulomas with bile duct injury and subsequent loss are more commonly seen on liver biopsy in patients with PBC. (See
         <a class="medical medical_review" href="/z/d/html/3621.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Progressive bile duct loss can also be found in patients with autoimmune cholangitis, a disorder that has similar clinical, biochemical, and histologic features of PBC but without antimitochondrial antibodies. Other autoimmune markers (eg, antinuclear and antismooth muscle antibodies) are frequently present. (See
         <a class="medical medical_review" href="/z/d/html/3636.html" rel="external">
          "Autoimmune hepatitis variants: Definitions and treatment", section on 'Autoimmune hepatitis-PBC overlaps'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/660.html" rel="external">
          "Primary sclerosing cholangitis in adults: Clinical manifestations and diagnosis", section on 'IgG4-associated cholangitis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary sclerosing cholangitis – Primary sclerosing cholangitis (PSC) typically involves both the intra- and extrahepatic biliary systems, resulting in fibrosis and stricturing. The diagnosis is established by cholangiography. Findings on liver biopsy are usually nonspecific, although a classic (but uncommonly seen) finding is fibrous obliteration of small bile ducts in an "onion skin" pattern. (See
         <a class="medical medical_review" href="/z/d/html/660.html" rel="external">
          "Primary sclerosing cholangitis in adults: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         T-cell-mediated (cellular) rejection of the liver allograft – The pathologic changes in acute T-cell-mediated (cellular) rejection of the liver allograft include bile duct damage that is characterized by nonsuppurative cholangitis of the bile duct epithelium. (See
         <a class="medical medical_review" href="/z/d/html/4587.html" rel="external">
          "Liver transplantation in adults: Clinical manifestations and diagnosis of acute T-cell mediated (cellular) rejection of the liver allograft"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic graft-versus-host disease – Chronic graft-versus-host disease is typically seen after allogenic bone marrow transplantation [
         <a href="#rid11">
          11
         </a>
         ]. Bile duct injury occurs when minor histocompatibility antigens expressed on the biliary epithelium are mismatched. Mononuclear cells react and ultimately obstruct small interlobular bile ducts. Patients may present with signs and symptoms of cholestasis (eg, jaundice, elevated liver biochemical tests). (See
         <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">
          "Clinical manifestations and diagnosis of chronic graft-versus-host disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sarcoidosis – Sarcoidosis is a systemic disease characterized by noncaseating granulomas, and most patients have liver involvement. When granulomas are present in the portal tract, adjacent bile ducts may be injured, which may result in ductopenia [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4317.html" rel="external">
          "Gastrointestinal, hepatic, pancreatic, and peritoneal sarcoidosis", section on 'Hepatic'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4072982315">
         <span class="h2">
          Infectious causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infectious causes that have been linked to bile duct loss and VBDS include viral and bacterial infections [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cytomegalovirus – Cases of VBDS in the setting of cytomegalovirus infection have been reported in immunocompromised patients [
         <a href="#rid13">
          13,14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic viral hepatitis – Bile duct injury and loss have been reported in patients with chronic viral hepatitis (hepatitis B virus [HBV] or hepatitis C virus infection [HCV]) [
         <a href="#rid15">
          15-17
         </a>
         ]. Fibrosing cholestatic hepatitis with severe bile duct loss has also been reported after liver and kidney transplantation in such patients [
         <a href="#rid15">
          15-17
         </a>
         ]. Recurrence of HBV or HCV following transplantation is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4584.html" rel="external">
          "Liver transplantation in adults: Preventing hepatitis B virus infection in liver transplant recipients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4583.html" rel="external">
          "Hepatitis C virus infection in liver transplant candidates and recipients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Epstein-Barr virus infection – Epstein-Barr virus infection has rarely been associated with bile duct loss [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8283.html" rel="external">
          "Clinical manifestations and treatment of Epstein-Barr virus infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Infections may also play a role in triggering or progression of immune-mediated biliary disease [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="local">
          'Immune-mediated disorders'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2844886431">
         <span class="h2">
          Malignancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Malignancies that have been associated with VBDS include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hodgkin lymphoma – Cholestasis with bile duct loss is a well-established but rare presentation of Hodgkin lymphoma [
         <a href="#rid19">
          19-23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4688.html" rel="external">
          "Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Liver infiltration by lymphoma cells in Hodgkin lymphoma has been seen in up to 50 percent of patients; however, progression to VBDS is rare [
         <a href="#rid23">
          23,24
         </a>
         ]. Management includes treatment of Hodgkin lymphoma, while patients with persistent cholestasis may be evaluated for liver transplantation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Macrophage activation syndrome – Macrophage activation syndrome is a form of hemophagocytic lymphohistiocytosis that occurs in patients with autoimmune diseases and that can rarely present with marked cholestasis, destructive small bile duct injury, and secondary biliary cholangitis. Histologically, the inflammatory changes and bile duct lesions are dominated by the presence of activated macrophages and T-cells, in particular CD8+ lymphocytes [
         <a href="#rid25">
          25,26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/87499.html" rel="external">
          "Clinical features and diagnosis of hemophagocytic lymphohistiocytosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3587864844">
         <span class="h2">
          Idiopathic adulthood ductopenia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Idiopathic adulthood ductopenia is an uncommon disorder in adults who have unexplained cholestatic liver disease and ductopenia despite evaluation with laboratory testing, imaging, and liver biopsy [
         <a href="#rid27">
          27-29
         </a>
         ]. In a single-center study including 2082 adult patients with intrahepatic bile duct injury, an underlying cause could not be identified in 25 patients (1 percent); thus, bile duct loss was regarded as idiopathic [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         Idiopathic adulthood ductopenia can be categorized as nonsevere or severe (the latter of which is also referred to as vanishing bile duct syndrome) [
         <a href="#rid9">
          9,31-33
         </a>
         ]. Determining the severity of hepatic ductopenia is discussed below. (See
         <a class="local">
          'Defining severity of ductopenia'
         </a>
         below.)
        </p>
        <p>
         Data limited to case reports and small case series have suggested that patients with nonsevere idiopathic bile duct loss are likely to recover, while some patients with extensive bile duct destruction may require liver transplantation [
         <a href="#rid31">
          31
         </a>
         ]. (See
         <a class="local">
          'Prognosis'
         </a>
         below.)
        </p>
        <p>
         It has been suggested that patients with idiopathic adulthood ductopenia may have several disorders with atypical features, including [
         <a href="#rid30">
          30
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Late-onset nonsyndromic paucity of intrahepatic bile ducts (see
         <a class="medical medical_review" href="/z/d/html/3584.html" rel="external">
          "Inherited disorders associated with conjugated hyperbilirubinemia"
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Small duct PSC without large duct involvement and without evidence of inflammatory bowel disease (see
         <a class="medical medical_review" href="/z/d/html/660.html" rel="external">
          "Primary sclerosing cholangitis in adults: Clinical manifestations and diagnosis", section on 'Small duct PSC'
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonsuppurative viral cholangitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autoimmune cholangitis in the absence of the typical autoantibodies (eg, lack of antimitochondrial antibody) (see
         <a class="medical medical_review" href="/z/d/html/3621.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis"
         </a>
         ).
        </p>
        <p>
        </p>
        <p>
         In addition, familial clustering of idiopathic adulthood ductopenia has been described, suggesting that genetic factors may play a role for some patients [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H620884038">
         <span class="h2">
          Patterns of clinical presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The timing of clinical presentation for patients with hepatic ductopenia and VBDS is variable and may depend on the underlying etiology. As an example, for patients with drug-induced liver injury (DILI), VBDS typically presents in one to six months after the offending drug was initiated [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="local">
          'Causes of ductopenia'
         </a>
         above.)
        </p>
        <p>
         Some patients may be asymptomatic and are initially identified based on laboratory abnormalities (eg, elevated alkaline phosphatase), while other patients may have symptoms of cholestasis such a jaundice, pruritus, and fatigue. For patients with chronic cholestasis, additional clinical features may include gallstone formation, hyperlipidemia, malabsorption, cutaneous xanthomas, and fat-soluble vitamin deficiencies [
         <a href="#rid35">
          35
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3598.html" rel="external">
          "Nutritional issues in adult patients with cirrhosis"
         </a>
         .)
        </p>
        <p>
         In addition, patients with progressive disease leading to cirrhosis may develop complications related to portal hypertension such as ascites and esophageal varices. (See
         <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">
          "Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1750917588">
         <span class="h2">
          Laboratory studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory abnormalities generally reflect cholestasis with elevations in alkaline phosphatase (often &gt;3 times the upper limit of normal), total serum bilirubin, and gamma-glutamyl transpeptidase. Moderate elevations in serum aminotransferases (alanine aminotransferase and aspartate aminotransferase) may also be present, but are rarely &gt;10 times the upper limit of normal. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115286.html" rel="external">
          "Laboratory test reference ranges in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with cholestasis and suspected VBDS, goals of the evaluation are to identify an underlying cause of intrahepatic cholestasis, exclude extrahepatic biliary obstruction, establish the diagnosis of VBDS, and determine the severity of bile duct loss.
        </p>
        <p class="headingAnchor" id="H482510461">
         <span class="h2">
          History and physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         The history includes a description of symptoms and use of prescription and nonprescription drugs.
        </p>
        <p>
         The physical examination should include an assessment for jaundice, hepatomegaly, skin excoriations from scratching, and stigmata of chronic liver disease (eg, ascites). (See
         <a class="medical medical_review" href="/z/d/html/89223.html" rel="external">
          "Overview of the evaluation of hepatomegaly in adults", section on 'Examining the liver'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2915800976">
         <span class="h2">
          Approach to testing
         </span>
        </p>
        <p class="headingAnchor" id="H404118366">
         <span class="h3">
          Laboratory evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory testing is performed to look for abnormalities in liver biochemistries and function and to identify possible causes of bile duct loss. For most patients, we obtain the following tests (see
         <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">
          "Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Hematologic abnormalities'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum aminotransferases – Alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alkaline phosphatase.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Total bilirubin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gamma-glutamyl transpeptidase.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum albumin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prothrombin time/international normalized ratio.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count, with a focus on evaluating for thrombocytopenia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antimitochondrial antibody.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autoimmune markers – Antismooth muscle antibody, antinuclear antibody.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serologies to exclude hepatitis B virus (HBV) and hepatitis C virus (HCV) infection – Hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B core antibody, and anti-HCV antibody.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cytomegalovirus assay. (See
         <a class="medical medical_review" href="/z/d/html/8291.html" rel="external">
          "Overview of diagnostic tests for cytomegalovirus infection"
         </a>
         .).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anti-Epstein-Barr virus (EBV) IgG and IgM antibodies. (See
         <a class="medical medical_review" href="/z/d/html/8318.html" rel="external">
          "Infectious mononucleosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The evaluation of patients with suspected extrapulmonary sarcoidosis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">
          "Clinical manifestations and diagnosis of sarcoidosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3285599132">
         <span class="h3">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Extrahepatic biliary obstruction should be excluded with imaging (eg, magnetic resonance cholangiopancreatography). Because VBDS is characterized by small duct injury, imaging tests are generally less helpful than liver biopsy for establishing the diagnosis. The cholangiogram is usually normal until extensive fibrosis from secondary biliary cirrhosis develops, in which the peripheral biliary tree may appeared "pruned" in areas of stenosis and ectasia. (See
         <a class="medical medical_review" href="/z/d/html/660.html" rel="external">
          "Primary sclerosing cholangitis in adults: Clinical manifestations and diagnosis", section on 'Small duct PSC'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h3">
          Liver biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         A liver biopsy is performed to establish the diagnosis and evaluate severity of liver disease. (See
         <a class="local">
          'Diagnosis'
         </a>
         below and
         <a class="local">
          'Defining severity of ductopenia'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3229008854">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of VBDS may be suspected in a patient with liver biochemical abnormalities consistent with cholestasis (alkaline phosphatase ≥2 times the upper limit of normal) in the absence of other conditions associated with cholestasis (eg, primary biliary cholangitis, primary sclerosing cholangitis, viral infections). (See
         <a class="local">
          'Causes of ductopenia'
         </a>
         above.)
        </p>
        <p>
         The diagnosis of VBDS is established by histologic examination acquired through liver biopsy and by excluding other conditions (eg, extrahepatic biliary obstruction) with imaging tests. VBDS is defined as loss of interlobular bile ducts in &gt;50 percent of portal areas, provided that the histologic specimen contains ≥10 portal tracts  (
         <a class="graphic graphic_picture graphicRef79064" href="/z/d/graphic/79064.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Diagnostic yield can be increased by immunostaining the liver biopsy specimen with cytokeratin 7 and 19, both of which identify biliary elements  (
         <a class="graphic graphic_picture graphicRef81586" href="/z/d/graphic/81586.html" rel="external">
          picture 2
         </a>
         and
         <a class="graphic graphic_picture graphicRef62914" href="/z/d/graphic/62914.html" rel="external">
          picture 3
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. Ductular proliferation may coexist with interlobular duct loss, and thus bile ductules must be distinguished from bile ducts. Bile ducts parallel hepatic artery branches of similar size, whereas ductular proliferation tends to appear near the limiting plate or within lobules [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H249544422">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of VBDS on microscopic examination of the liver includes ischemic hepatic necrosis with resultant bile duct injury and loss, acute T-cell mediated rejection, and primary sclerosing cholangitis. The clinical setting (ie, liver transplant recipient), findings on imaging studies (ie, biliary strictures) can help distinguish among these entities. (See
         <a class="medical medical_review" href="/z/d/html/4596.html" rel="external">
          "Liver transplantation in adults: Endoscopic management of biliary adverse events"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/660.html" rel="external">
          "Primary sclerosing cholangitis in adults: Clinical manifestations and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H3334093901">
         <span class="h2">
          Measures for all patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with cholestasis and hepatic ductopenia (loss of ≥25 percent of intrahepatic small bile ducts on liver biopsy) without a clear cause identified on laboratory testing, imaging, or liver histology, general measures include  (
         <a class="graphic graphic_algorithm graphicRef131194" href="/z/d/graphic/131194.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Avoid drugs associated with liver injury
         </strong>
         – Drugs that have been associated with liver injury are avoided. (See
         <a class="medical medical_review" href="/z/d/html/3571.html" rel="external">
          "Drug-induced liver injury"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The National Institutes of Health maintains a
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK547852%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4try0%2B5669jWuE9Ds1a1khkWX5vkEjVCKubKK5acgUH7v%2Fw%3D%3D&amp;TOPIC_ID=3595" target="_blank">
          searchable database
         </a>
         of drugs and dietary supplements that have been associated with drug-induced liver injury (DILI).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Abstain from alcohol
         </strong>
         – We advise patients with hepatic ductopenia to abstain from alcohol.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Manage symptoms
         </strong>
         – Pruritus is a characteristic cholestatic symptom in patients with bile duct loss, and the approach to management is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3607.html" rel="external">
          "Pruritus associated with cholestasis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lifestyle modifications
         </strong>
         – We advise patients to maintain an ideal body weight through dietary therapy and exercise. Lifestyle interventions to promote weight loss and maintain ideal body weight are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">
          "Obesity in adults: Overview of management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunizations
         </strong>
         –
         <strong>
         </strong>
         Vaccinations for hepatitis A virus and hepatitis B virus are given to patients without serologic evidence of immunity. Additional vaccines for patients with chronic liver disease include pneumococcal vaccination and immunizations that are given to the general population (eg, influenza)  (
         <a class="graphic graphic_figure graphicRef82634" href="/z/d/graphic/82634.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef62130" href="/z/d/graphic/62130.html" rel="external">
          figure 2
         </a>
         ). Immunization schedules are described separately. (See
         <a class="medical medical_review" href="/z/d/html/3891.html" rel="external">
          "Immunizations for adults with chronic liver disease", section on 'Vaccines in chronic liver disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hepatology consultation
         </strong>
         –
         <strong>
         </strong>
         We suggest that patients with hepatic ductopenia and VBDS are referred to a hepatologist for long-term management.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2470692214">
         <span class="h2">
          Defining severity of ductopenia
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of patients with histologic evidence of hepatic ductopenia is guided by the severity of bile duct loss, provided that the pathologic specimen contained at least 10 portal tracts [
         <a href="#rid9">
          9
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonsevere hepatic ductopenia – Loss of interlobular bile ducts in 25 to 50 percent of portal tracts
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe hepatic ductopenia (also referred to as VBDS) – Loss of interlobular bile ducts in &gt;50 percent of portal tracts
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3761849284">
         <span class="h2">
          Patients with nonsevere ductopenia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with nonsevere idiopathic ductopenia are initially managed with supportive measures only, based mainly on clinical experience as published data have been limited. (See
         <a class="local">
          'Measures for all patients'
         </a>
         above and
         <a class="local">
          'Patients with severe ductopenia (vanishing bile duct syndrome)'
         </a>
         below.)
        </p>
        <p>
         Patients are monitored with liver biochemical tests (ie, alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase, total bilirubin) every one to three months until alkaline phosphatase is &lt;2 times the upper limit of normal. For patients with nonsevere ductopenia who do not have improvement in alkaline phosphatase within one to three months,
         <a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">
          ursodeoxycholic acid
         </a>
         (UDCA) is typically initiated, similar to treatment for severe ductopenia (vanishing bile duct syndrome). (See
         <a class="local">
          'Patients with severe ductopenia (vanishing bile duct syndrome)'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1844812767">
         <span class="h2">
          Patients with severe ductopenia (vanishing bile duct syndrome)
         </span>
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h3">
          Initial therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with severe ductopenia without a clear etiology, initial therapy is UDCA at a total daily dose of 13 to 15 mg/kg orally and usually administered twice daily. Improvement in symptoms (eg, pruritus) is typically observed shortly after starting UDCA, while liver biochemical tests (ie, alkaline phosphatase) may remain chronically elevated.
        </p>
        <p>
         After initiating therapy, liver biochemical testing (ie, ALT, AST, alkaline phosphatase and total bilirubin) is performed at one to three-month intervals. UDCA should be continued until alkaline phosphatase is &lt;2 times the upper limit of normal. When cholestasis has resolved, we gradually taper UDCA over two to three months. After UDCA is discontinued, we monitor liver biochemical tests for an additional three to six months.
        </p>
        <p>
         Patients without improvement in alkaline phosphatase despite UDCA therapy are monitored for long-term complications of cholestasis (eg, fat-soluble vitamin deficiency, metabolic bone disease) and for progression to biliary cirrhosis. (See
         <a class="local">
          'Subsequent management'
         </a>
         below.)
        </p>
        <p>
         UDCA is generally well-tolerated with few adverse effects (eg, modest weight gain [approximately 3 kg]) [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         Data supporting UDCA as pharmacologic therapy for VBDS are limited to few case reports that have described improvement in symptoms and liver biochemical tests for patients with severe ductopenia associated with DILI [
         <a href="#rid3">
          3,37,38
         </a>
         ]. However, the impact of UDCA on disease progression is unknown.
         <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">
          Cholestyramine
         </a>
         , a drug that is commonly used for pruritus, may decrease the bioavailability of UDCA secondary to intraluminal binding; thus, these drugs should be given at separate intervals. (See
         <a class="medical medical_review" href="/z/d/html/3607.html" rel="external">
          "Pruritus associated with cholestasis"
         </a>
         .)
        </p>
        <p>
         UDCA, a hydrophilic bile acid, is thought to exert its beneficial effects in cholestatic liver disorders through several mechanisms of action including [
         <a href="#rid39">
          39-41
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased hydrophilic index of the circulating bile acid pool
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stimulation of hepatocellular and ductular secretions
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cytoprotection against hydrophobic bile acid- and cytokine-induced injury
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunomodulation and anti-inflammatory effects
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H33">
         <span class="h3">
          Subsequent management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who do not have liver biochemical improvement with UDCA or who develop progressive debilitating symptoms (eg, pruritus) are monitored by a hepatologist with a focus on symptomatic relief and anticipating complications. (See
         <a class="medical medical_review" href="/z/d/html/3607.html" rel="external">
          "Pruritus associated with cholestasis"
         </a>
         .)
        </p>
        <p>
         Patients are monitored for signs of disease progression (eg, jaundice, complications of portal hypertension such as ascites, variceal bleeding) and for complications of chronic cholestasis (eg, fat soluble vitamin deficiency, metabolic bone disease). For patients with idiopathic ductopenia, management of cholestasis-related complications is similar to the approach for patients with cholestasis related to primary biliary cholangitis, and this is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3623.html" rel="external">
          "Overview of the management of primary biliary cholangitis", section on 'Complications'
         </a>
         .)
        </p>
        <p>
         Patients with chronic cholestasis who progress to decompensated cirrhosis should be referred for liver transplantation evaluation. (See
         <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">
          "Cirrhosis in adults: Overview of complications, general management, and prognosis", section on 'Decompensated cirrhosis'
         </a>
         .)
        </p>
        <p>
         Successful liver transplantation without disease recurrence has been described in adult patients with idiopathic ductopenia [
         <a href="#rid42">
          42
         </a>
         ]. The selection of patients for liver transplantation and the pretransplant evaluation are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4585.html" rel="external">
          "Liver transplantation in adults: Patient selection and pretransplantation evaluation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2327085282">
         <span class="h3">
          Investigational therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of immunosuppressive agents (eg, glucocorticoids,
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ) for treating VBDS and chronic cholestasis has been reported [
         <a href="#rid35">
          35,43
         </a>
         ]. The rationale for using immunosuppression has been that several etiologies of ductopenia appear to be related to an immune-mediated cause. (See
         <a class="local">
          'Immune-mediated disorders'
         </a>
         above.)
        </p>
        <p>
         However, we do not typically use immunosuppressive agents because the benefit remains uncertain, while there may be exceptions to this approach (eg, patients with intractable pruritus who have not responded to UDCA, patients with histologic features suggestive of immune-mediated pathology).
        </p>
        <p class="headingAnchor" id="H2661418654">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The natural history of acquired bile duct loss resulting in hepatic ductopenia has often been unpredictable and has been described as two potential outcomes [
         <a href="#rid23">
          23
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gradual recovery – Biliary epithelial regeneration and resolution of symptoms typically occurs gradually over a period of months to years. Bile duct loss may be reversible and is preceded by a ductular proliferation, followed by reappearance of bile ducts [
         <a href="#rid28">
          28,31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Irreversible bile duct loss – Progressive, irreversible bile duct loss leads to extensive ductopenia, biliary obstruction, and cirrhosis.
        </p>
        <p>
        </p>
        <p>
         For some patients, idiopathic ductopenia has been associated with a poor prognosis. Small case series have suggested that up to 50 percent of patients with idiopathic severe ductopenia progress to liver failure requiring liver transplantation [
         <a href="#rid27">
          27,30,34
         </a>
         ]. However, some patients appear to progress slowly (eg, over &gt;10 years) [
         <a href="#rid32">
          32
         </a>
         ]. The development of decompensated cirrhosis reflects progressive biliary obstruction and the development of secondary biliary cirrhosis. (See
         <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">
          "Cirrhosis in adults: Overview of complications, general management, and prognosis", section on 'Decompensated cirrhosis'
         </a>
         .)
        </p>
        <p>
         Limited data have suggested that the prognosis may be more favorable for patients with nonsevere hepatic ductopenia on liver biopsy or who are diagnosed after age 40 years [
         <a href="#rid30">
          30,44
         </a>
         ]. (See
         <a class="local">
          'Defining severity of ductopenia'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1600366550">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116714.html" rel="external">
          "Society guideline links: Drug-induced liver injury"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H35">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Background
         </strong>
         – Vanishing bile duct syndrome (VBDS) is an uncommon, acquired, but potentially serious form of cholestatic liver disease. Hepatic ductopenia (a pathologic description; also designated as bile duct paucity) refers to a reduction in the number of intrahepatic bile ducts, a process that may lead to cholestasis. VBDS is manifested histologically by severe hepatic ductopenia, defined as a loss of the intralobular bile ducts in &gt;50 percent of small portal tracts. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Some patients with hepatic ductopenia may be asymptomatic, while others may have symptoms of cholestasis such a jaundice, pruritus, and fatigue. Laboratory abnormalities generally reflect cholestasis with elevations in alkaline phosphatase (often &gt;3 times the upper limit of normal), total bilirubin, and gamma-glutamyl transpeptidase. Moderate elevations in serum aminotransferases (alanine aminotransferase and aspartate aminotransferase) may also be present, but are rarely &gt;10 times the upper limit of normal. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – For patients with suspected VBDS, the evaluation includes history and physical examination, laboratory studies, imaging to exclude extrahepatic biliary obstruction, and liver biopsy. Goals of the diagnostic evaluation are to identify an underlying cause of intrahepatic cholestasis, exclude extrahepatic biliary obstruction, establish the diagnosis of VBDS, and determine the severity of bile duct loss. (See
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of VBDS is established by histologic examination acquired through liver biopsy and by excluding other conditions (eg, extrahepatic biliary obstruction) with imaging tests. VBDS is defined as loss of interlobular bile ducts in &gt;50 percent of portal tracts, provided that the histologic specimen contained at least 10 portal tracts. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – For patients with evidence of cholestasis and hepatic ductopenia (loss of ≥25 percent of intrahepatic small bile ducts on liver biopsy) without a clear cause identified on laboratory testing, imaging, or liver histology, general measures include  (
         <a class="graphic graphic_algorithm graphicRef131194" href="/z/d/graphic/131194.html" rel="external">
          algorithm 1
         </a>
         ) (see
         <a class="local">
          'Measures for all patients'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Manage symptoms that are associated with cholestasis (eg, pruritus) (see
         <a class="medical medical_review" href="/z/d/html/3607.html" rel="external">
          "Pruritus associated with cholestasis"
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Avoid drugs associated with liver injury.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Abstain from alcohol.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Maintain ideal body weight through dietary therapy and exercise.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vaccinations for hepatitis A virus and hepatitis B virus are given to patients without serologic evidence of immunity. (See
         <a class="medical medical_review" href="/z/d/html/3891.html" rel="external">
          "Immunizations for adults with chronic liver disease", section on 'Vaccines in chronic liver disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hepatology consultation for long-term management.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with severe idiopathic ductopenia (ie, VBDS), we suggest
         <a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">
          ursodeoxycholic acid
         </a>
         (UDCA) as first-line therapy rather than supportive measures alone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). UDCA has been associated with improvement in liver biochemistries and symptoms. UDCA at a total daily dose of 13 to 15 mg/kg is typically administered in two divided doses and is continued until alkaline phosphatase is &lt;2 times the upper limit of normal. (See
         <a class="local">
          'Initial therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – The natural history of hepatic ductopenia has been described as two potential outcomes: gradual recovery that typically occurs over months to years, or progressive, irreversible bile duct loss that may lead to biliary obstruction and cirrhosis. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H108882459">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Donald Jensen, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Geubel AP, Sempoux CL. Drug and toxin-induced bile duct disorders. J Gastroenterol Hepatol 2000; 15:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakanuma Y, Tsuneyama K, Harada K. Pathology and pathogenesis of intrahepatic bile duct loss. J Hepatobiliary Pancreat Surg 2001; 8:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao Z, Bao L, Yu X, et al. Acute vanishing bile duct syndrome after therapy with cephalosporin, metronidazole, and clotrimazole: A case report. Medicine (Baltimore) 2017; 96:e8009.
          </a>
         </li>
         <li class="breakAll">
          Carpenter R, Brady MF.. StatPearls, StatPearls Publishing, Treasure Island (FL) 2020.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doherty GJ, Duckworth AM, Davies SE, et al. Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. ESMO Open 2017; 2:e000268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonkovsky HL, Kleiner DE, Gu J, et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology 2017; 65:1267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adike A, Smith ML, Chervenak A, Vargas HE. Hydroxycut-related Vanishing Bile Duct Syndrome. Clin Gastroenterol Hepatol 2017; 15:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conrad MA, Cui J, Lin HC. Sertraline-Associated Cholestasis and Ductopenia Consistent with Vanishing Bile Duct Syndrome. J Pediatr 2016; 169:313.
          </a>
         </li>
         <li class="breakAll">
          LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD) 2012.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Desmet VJ. Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol 1997; 26 Suppl 1:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeh KH, Hsieh HC, Tang JL, et al. Severe isolated acute hepatic graft-versus-host disease with vanishing bile duct syndrome. Bone Marrow Transplant 1994; 14:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farouj NE, Cadranel JF, Mofredj A, et al. Ductopenia related liver sarcoidosis. World J Hepatol 2011; 3:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hindupur S, Yeung M, Shroff P, et al. Vanishing bile duct syndrome in a patient with advanced AIDS. HIV Med 2007; 8:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tyagi I, Puri AS, Sakhuja P, et al. Co-occurrence of cytomegalovirus-induced vanishing bile duct syndrome with papillary stenosis in HIV infection. Hepatol Res 2013; 43:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delladetsima JK, Makris F, Psichogiou M, et al. Cholestatic syndrome with bile duct damage and loss in renal transplant recipients with HCV infection. Liver 2001; 21:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffmann RM, Günther C, Diepolder HM, et al. Hepatitis C virus infection as a possible risk factor for ductopenic rejection (vanishing bile duct syndrome) after liver transplantation. Transpl Int 1995; 8:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jung S, Lee HC, Han JM, et al. Four cases of hepatitis B virus-related fibrosing cholestatic hepatitis treated with lamivudine. J Gastroenterol Hepatol 2002; 17:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kikuchi K, Miyakawa H, Abe K, et al. Vanishing bile duct syndrome associated with chronic EBV infection. Dig Dis Sci 2000; 45:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hubscher SG, Lumley MA, Elias E. Vanishing bile duct syndrome: a possible mechanism for intrahepatic cholestasis in Hodgkin's lymphoma. Hepatology 1993; 17:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeBenedet AT, Berg CL, Enfield KB, et al. A case of vanishing bile duct syndrome and IBD secondary to Hodgkin's lymphoma. Nat Clin Pract Gastroenterol Hepatol 2008; 5:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greca RD, Cunha-Silva M, Costa LBE, et al. Vanishing bile duct syndrome related to DILI and Hodgkin lymphoma overlap: A rare and severe case. Ann Hepatol 2020; 19:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong KM, Chang CS, Wu CC, Yin HL. Hodgkin's lymphoma-related vanishing bile duct syndrome: a case report and literature review. Kaohsiung J Med Sci 2013; 29:636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakhit M, McCarty TR, Park S, et al. Vanishing Bile Duct Syndrome in Hodgkin's Lymphoma: A Single Center Experience and Clinical Pearls. J Clin Gastroenterol 2016; 50:688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liangpunsakul S, Kwo P, Koukoulis GK. Hodgkin's disease presenting as cholestatic hepatitis with prominent ductal injury. Eur J Gastroenterol Hepatol 2002; 14:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bihl F, Emmenegger U, Reichen J, et al. Macrophage activating syndrome is associated with lobular hepatitis and severe bile duct injury with cholestasis. J Hepatol 2006; 44:1208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li H, Li X, Liao XX, et al. Drug associated vanishing bile duct syndrome combined with hemophagocytic lymphohistiocytosis. World J Gastrointest Endosc 2012; 4:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ludwig J, Wiesner RH, LaRusso NF. Idiopathic adulthood ductopenia. A cause of chronic cholestatic liver disease and biliary cirrhosis. J Hepatol 1988; 7:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Domínguez-Antonaya M, Coba-Ceballos JM, Gómez-Rubio M, et al. Idiopathic adulthood ductopenia: a diagnosis: two clinicopathologic courses. J Clin Gastroenterol 2000; 30:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilal M, Kazemi A, Babich M. Idiopathic Adulthood Ductopenia: 'It Is Out There'. Case Rep Gastroenterol 2016; 10:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ludwig J. Idiopathic adulthood ductopenia: an update. Mayo Clin Proc 1998; 73:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khanlou H, Sass D, Rothstein K, et al. Idiopathic adulthood ductopenia: case report and review of the literature. Arch Intern Med 2000; 160:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreno A, Carreño V, Cano A, González C. Idiopathic biliary ductopenia in adults without symptoms of liver disease. N Engl J Med 1997; 336:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller C, Ulrich W, Penner E. Manifestation late in life of idiopathic adulthood ductopenia. Liver 1995; 15:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burak KW, Pearson DC, Swain MG, et al. Familial idiopathic adulthood ductopenia: a report of five cases in three generations. J Hepatol 2000; 32:159.
          </a>
         </li>
         <li class="breakAll">
          LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Vanishing Bile Duct Syndrome. [Updated 2019 Dec 11]. https://www.ncbi.nlm.nih.gov/books/NBK548715/ (Accessed on June 22, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siegel JL, Jorgensen R, Angulo P, Lindor KD. Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis. J Clin Gastroenterol 2003; 37:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith LA, Ignacio JR, Winesett MP, et al. Vanishing bile duct syndrome: amoxicillin-clavulanic acid associated intra-hepatic cholestasis responsive to ursodeoxycholic acid. J Pediatr Gastroenterol Nutr 2005; 41:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Brien CB, Shields DS, Saul SH, Reddy KR. Drug-induced vanishing bile duct syndrome: response to ursodiol. Am J Gastroenterol 1996; 91:1456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012; 36 Suppl 1:S3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002; 36:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pusl T, Beuers U. Ursodeoxycholic acid treatment of vanishing bile duct syndromes. World J Gastroenterol 2006; 12:3487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rios R, Herrero JI, Quiroga J, et al. Idiopathic adulthood ductopenia: long-term follow-up after liver transplantation. Dig Dis Sci 2001; 46:1420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okan G, Yaylaci S, Peker O, et al. Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus. World J Gastroenterol 2008; 14:4697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglass KM, Willner IR, Glenn DJ, Jones RM. Idiopathic Adulthood Ductopenia Causing Cirrhosis. ACG Case Rep J 2020; 7:e00349.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3595 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11129214" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Drug and toxin-induced bile duct disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11521175" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Pathology and pathogenesis of intrahepatic bile duct loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28885366" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Acute vanishing bile duct syndrome after therapy with cephalosporin, metronidazole, and clotrimazole: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28885366" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Acute vanishing bile duct syndrome after therapy with cephalosporin, metronidazole, and clotrimazole: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29081991" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27981596" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27151488" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Hydroxycut-related Vanishing Bile Duct Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26597434" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Sertraline-Associated Cholestasis and Ductopenia Consistent with Vanishing Bile Duct Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26597434" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Sertraline-Associated Cholestasis and Ductopenia Consistent with Vanishing Bile Duct Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9138126" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Vanishing bile duct syndrome in drug-induced liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7994249" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Severe isolated acute hepatic graft-versus-host disease with vanishing bile duct syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22509431" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Ductopenia related liver sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17305935" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Vanishing bile duct syndrome in a patient with advanced AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23437911" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Co-occurrence of cytomegalovirus-induced vanishing bile duct syndrome with papillary stenosis in HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11318976" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Cholestatic syndrome with bile duct damage and loss in renal transplant recipients with HCV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7576016" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Hepatitis C virus infection as a possible risk factor for ductopenic rejection (vanishing bile duct syndrome) after liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11982709" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Four cases of hepatitis B virus-related fibrosing cholestatic hepatitis treated with lamivudine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10695629" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Vanishing bile duct syndrome associated with chronic EBV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7678577" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Vanishing bile duct syndrome: a possible mechanism for intrahepatic cholestasis in Hodgkin's lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18174907" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A case of vanishing bile duct syndrome and IBD secondary to Hodgkin's lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31537508" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Vanishing bile duct syndrome related to DILI and Hodgkin lymphoma overlap: A rare and severe case.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24183359" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Hodgkin's lymphoma-related vanishing bile duct syndrome: a case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27203429" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Vanishing Bile Duct Syndrome in Hodgkin's Lymphoma: A Single Center Experience and Clinical Pearls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11953700" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Hodgkin's disease presenting as cholestatic hepatitis with prominent ductal injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16618513" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Macrophage activating syndrome is associated with lobular hepatitis and severe bile duct injury with cholestasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22912913" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Drug associated vanishing bile duct syndrome combined with hemophagocytic lymphohistiocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3057064" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Idiopathic adulthood ductopenia. A cause of chronic cholestatic liver disease and biliary cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10730931" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Idiopathic adulthood ductopenia: a diagnosis: two clinicopathologic courses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27403109" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Idiopathic Adulthood Ductopenia: 'It Is Out There'.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9511789" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Idiopathic adulthood ductopenia: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10761970" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Idiopathic adulthood ductopenia: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9062092" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Idiopathic biliary ductopenia in adults without symptoms of liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8544645" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Manifestation late in life of idiopathic adulthood ductopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10673081" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Familial idiopathic adulthood ductopenia: a report of five cases in three generations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10673081" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Familial idiopathic adulthood ductopenia: a report of five cases in three generations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12869893" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16205517" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Vanishing bile duct syndrome: amoxicillin-clavulanic acid associated intra-hepatic cholestasis responsive to ursodeoxycholic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8678017" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Drug-induced vanishing bile duct syndrome: response to ursodiol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23141891" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12198643" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16773706" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11478493" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Idiopathic adulthood ductopenia: long-term follow-up after liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18698687" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32337312" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Idiopathic Adulthood Ductopenia Causing Cirrhosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
